DiaMedica Therapeutics Inc. Common Stock
DMACDiaMedica Therapeutics Inc. is a clinical-stage biopharmaceutical company focused on developing therapies for neurological and kidney diseases. It leverages its proprietary DM200 monoclonal antibody platform to target complement-mediated diseases, aiming to address unmet medical needs in stroke, neurodegeneration, and kidney disorders.
Company News
The acute ischemic stroke market is expected to grow significantly through 2036, driven by increased symptom awareness, advances in acute stroke care, and a robust pipeline of innovative therapies. Key candidates in development include lenzocimab, DM199, milvexian, and BB-031. The US accounts for the largest market share, with approximately 1.8 m...
DiaMedica (DMAC) rises 10% as it doses the first patient in the relaunch of its pivotal study evaluating the lead candidate, DM199, to treat acute ischemic stroke.
DiaMedica Therapeutics (DMAC) is technically in oversold territory now, so the heavy selling pressure might have exhausted. This along with strong agreement among Wall Street analysts in raising earnings estimates could lead to a trend reversal for the stock.
Here is how Cardiol Therapeutics Inc. (CRDL) and DiaMedica Therapeutics, Inc. (DMAC) have performed compared to their sector so far this year.
Here is how DiaMedica Therapeutics, Inc. (DMAC) and DermTech, Inc. (DMTK) have performed compared to their sector so far this year.
